Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals — Investor Presentation (December 2021)

35 slides from Longboard Pharmaceuticals's investor presentation, Dec 1, 2021

  1. Slide 1: December 2021 Corporate Presentation

    December 2021 Corporate Presentation Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. (“we,” “Longboard” or the “Company”), including statements regarding: our future results of operations and financial position; business strategy; the timing, costs and conduct of ou

  3. Slide 3: Investment Thesis

    Investment Thesis Definitions: DEEs = developmental and epileptic encephalopathies; ALS =amyotrophic lateral sclerosis; CB2 = cannabinoid type 2 (CB2) receptor; S1P = sphingosine 1-phosphate (S1P) receptor modulators Three drug candidates internally developed by Arena which represents a culmination

  4. Slide 4: Leadership Team

    Leadership Team Kevin Lind 23+ years experience in healthcare investing in special situations and pharmaceuticals; as well as executive leadership in life sciences Chief Medical Officer Phil Perera, M.D 35+ years clinical research leadership, including research, development and approval of small mol

  5. Slide 5: Independent Directors

    Independent Directors February 2021 • 5 Vince Aurentz Corinne Le Goff, Pharm D. Jane Tiller, MBChB, FRCPsych Casey Lynch Phillip Schneider Paul Sekhri

  6. Slide 6: LP352: Oral, Centrally Acting 5-HT2c Receptor Superagonist

    Oral, Centrally Acting 5-HT2c Receptor Superagonist Targeting Seizures Associated with Multiple Refractory Epilepsies LP352

  7. Slide 7: LP352, A Centrally Acting 5-HT2c Superagonist Targeting Multiple Epileptic Indications

    LP352, A Centrally Acting 5-HT2c Superagonist Targeting Multiple Epileptic Indications with Significant Unmet Need *Arena designed LP352 to be a differentiated drug candidate; the design features listed above is the intended profile, but there is no guarantee continuing clinical or non-clinical stud

  8. Slide 8: There is a Large Unsatisfied Patient Population in Epilepsy

    There is a Large Unsatisfied Patient Population in Epilepsy Epilepsy is uncontrolled for ~25% of children1 and up to 50% of adults2 Developmental and Epileptic Encephalopathy (DEE) is a group of severe epilepsies characterized by seizures, often drug-resistant, and encephalopathy Over 25 Syndromes D

  9. Slide 9: Treatment Paradigm for DEEs

    Treatment Paradigm for DEEs is Characterized by Initial Short-Term Trial of Monotherapy, Followed by Polytherapy Strategies 4th Line Devices / Procedures (e.g., vagal nerve stimulation) Continue AED Polytherapy 3rd Line Ketogenic Diet Initiate AED Polytherapy 2nd Line Add or switch AED Prescribe fir

  10. Slide 10: Role of 5-HT2c Receptors in Epilepsy

    Role of 5-HT2c Receptors in Epilepsy 5-HT2c modulation of hippocampal pyramidal GABAergic neurons suppresses hyperexcitability 5-HT2c KO mice display spontaneous seizures and decreased threshold for proconvulsant stimuli m-CPP (5-HT2c) increases threshold for PTZ- and electroshock induced myoclonic

  11. Slide 11: 5-HT2c Agonists Have Shown Real World Evidence in Epilepsy

    5-HT2c Agonists Have Shown Real World Evidence in Epilepsy, However Significant Unmet Need Remains FINTEPLA® DS (fenfluramine, ZX008) Lorcaserin History Pulled from market in 1997 because of high incidence of cardiac valvular abnormalities found in patients (originally marketed as appetite suppressa

  12. Slide 12: Real World Clinical Evidence of 5-HT2c Agonism Efficacy with Lorcaserin

    Real World Clinical Evidence of 5-HT2c Agonism Efficacy with Lorcaserin 35 refractory patients ranging from 3 - 40 years old (including DS, LGS, treatment resistant focal and generalized seizures) Failed at least 5 and up to 9+ previous AED medications 47.7% median percentage reduction in mean month

  13. Slide 13: Patient Age Weight (kg) 35 Dose .25 .27 .19 .32 .31 Prior AED’s CLZ,

    Patient 1 2 3 4 5 Age 10 18 10 7 14 Weight (kg) 28 46 23 24 35 Dose .25 .27 .19 .32 .31 Prior AED’s CLZ, CZP, KD, LMT, LBT, PRM, OXC, RUF, TPX, VPA CBZ, CBD, CLZ, CLB, CZP, FBM, LMT, LVT, PRM, PHB, TPM, VPA, CC, KD, VNS ESM, FBM, LMT, LVT, MSM, VPA, VMP, ZNM, KD CZP, ESM, LVT, LZP, STP, TPM, ZNM, KD

  14. Slide 14: Fenfluramine Approved for DS Associated Seizures, but Removed from Market in 1997

    Fenfluramine Approved for DS Associated Seizures, but Removed from Market for Weight Loss in 1997 After Link to VHD and PAH Retrospective Analysis Fenfluramine Treatment in Dravet Syndrome Pt Age Dose Daily (mg/kg) No. of Echos Performed Previous Echo Most Recent Echo (2016) 1 30 .12 6 2012: slightl

  15. Slide 15: Limitations of FINTEPLA

    Limitations of FINTEPLA® FINTEPLA is Non-Selective FINTEPLA is a 5-HT2 agonist with activity on the 5-HT2b receptor subtype, therefore, can cause off-target cardiovascular adverse events And Carries Fenfluramine’s Stigma Black box warning and Risk Evaluation and Mitigation Strategy (REMS) program re

  16. Slide 16: LP352 Designed to be a Next-Generation 5-HT2c with Greater Selectivity

    LP352 Designed to be a Next-Generation 5-HT2c with Greater Selectivity and Specificity Serotonin Receptor Subtype EC50, nM Ki, nM Selectivity 2c vs 2b Selectivity 2c vs 2a Noted Side Effects LP352 5-HT2c Superagonist 5-HT2c ~120 ~50 >200x >200x Headache, Nausea, Weight Loss 5-HT2b >10,000 >10,000 5-

  17. Slide 17: LP352 Ph 1 Trial – Favorable Safety, Tolerability, PK and PD

    LP352 Ph 1 Trial – Favorable Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Observed Single ascending dose Single-dose food effect (N=40) Multiple ascending dose Dose titration (N=43) Pharmacokinetics Target plasma exposure (Cmin) based on prolactin PK/PD No clinically meaningful effect

  18. Slide 18: LP352 Ph 1b/2a PACIFIC Study in Patients with DEEs

    LP352 Ph 1b/2a PACIFIC Study in Patients with DEEs A double-blind, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of LP352 and Key Efficacy Signals: Evaluate reduction in seizures across a broad group of epilepsies Identify potential indications for pivotal studies

  19. Slide 19: LP352 Summary

    LP352 Summary LP352’s potential for receptor selectivity and specificity position it as an attractive compound to evaluate for the treatment of DEEs Completed Ph 1 SAD/MAD trials Next steps: Ph 1b/2a trial expected to start Q1 2022 Addressable and unsatisfied orphan disease opportunity Clinical Tria

  20. Slide 20: LP143 Centrally Acting Full Agonist to the CB2 Receptor

    LP143 Centrally Acting Full Agonist to the Cannabinoid Type 2 (CB2) Receptor Targeting a Broad Range of Neurodegenerative Diseases

  21. Slide 21: LP143 Summary

    LP143 Summary Potential to Redefine Treatment of Neurodegenerative Diseases LP143: Designed to be a centrally acting full CB2 agonist with the following preclinical observations and design features: High brain-to-plasma ratio Demonstrated to be 1000x more selective for CB2 than CB1 in preclinical mo

  22. Slide 22: ALS is an Orphan Motor Neuron Disease with Poor Prognosis

    ALS is an Orphan Motor Neuron Disease with Poor Prognosis Average time from diagnosis to paralysis and death from respiratory failure is 2-5 years Progressive neurodegenerative disease that affects upper and lower motor neurons (MNs) Characterized by rapid progression of muscle wasting and weakness.

  23. Slide 23: Neuroinflammation Mediated by Microglial Activation in ALS Progression

    Neuroinflammation Mediated by Microglial Activation Plays an Important Role in ALS Progression Inflammatory processes in non-neuronal cells have been shown to play an important role in driving motor neuron degeneration Studies of ALS animal models show that microglial cells initially have a neuropro

  24. Slide 24: Increased CB2 Receptor Expression in Brain of ALS Patients

    Increased CB2 Receptor Expression in Brain of ALS Patients Human ALS motor cortex – increase in CB2 receptors (Fig 1), but no changes in CB1 receptors or monoacylglycerol lipase (MAGL) and Fatty Acid Amide Hydrolase (FAAH) enzymes (Fig 2) Figure 1 Figure 2 CB2 immunofluorescence CB2 immunoblot Contr

  25. Slide 25: Increased CB2 Receptor Expression in Spinal Cord of ALS Patients

    Increased CB2 Receptor Expression in Spinal Cord of ALS Patients ALS spinal cord (A-D) CB2 receptors are increased in lesion areas with microglial cells (CD68 marker) (E-F) CB2-ALS CB2-ALS CD68-ALS CD68-ALS % area CB2 % area immunoreactivity B C A D NAWM non affected white matter WM white matter; VH

  26. Slide 26: Preclinical Data Indicate CB2 Agonism Could Restore Neuroprotective Phenotype

    Preclinical Data Indicate that CB2 Agonism Has the Potential to Restore the Neuroprotective Phenotype of Microglial Cells CB2 activation has shown beneficial effects in animal models of ALS: Reduced microglial mediated neuroinflammation, excitotoxicity and oxidative cell damage Inhibited release of

  27. Slide 27: Increased CB2 Receptor Expression in Experimental Model of ALS

    Increased CB2 Receptor Expression in Experimental Model of ALS (hSOD1G93A mice) Transgenic mice overexpressing human mutated SOD-1 enzyme Validated ALS model hSOD1G93A - Increase in CB2, but not CB1 receptors Receptor mRNA Fold-change (Relative to age-matched WT-OE) CB2-mRNA CB1-mRNA G93A spinal cor

  28. Slide 28: CB2 Receptor Upregulated and CB2 Agonist Prolonged Survival in ALS Model

    CB2 Receptor was Upregulated and Treatment with CB2 Receptor Agonist Prolonged Survival in Model of ALS CB2 receptor agonist AM1241 has demonstrated delayed loss of motor function and improved survival in an experimental mouse model of ALS (hSOD1G93A) Receptor mRNA Fold-Change (Relative To Age-Match

  29. Slide 29: LP143 Summary

    LP143 Summary CB2 pathway involved in multiple neuroinflammatory orphan disease state opportunities including ALS Centrally acting full agonist of the CB2 receptor with high brain to plasma ratio and high oral bioavailability Selective CB2 receptor agonist delayed loss of motor function and improved

  30. Slide 30: LP659 Centrally Acting S1P Receptor Modulator

    LP659 Centrally Acting Sphingosine-1-Phosphate (S1P) Receptor Modulator Targeting a Range of Neurodegenerative Diseases

  31. Slide 31: LP659 Potential to Redefine Treatment of Neurodegenerative Diseases

    Neuron S1P1, S1P2, S1P3 and S1P5 Reduced dendritic spine loss Restored neuronal function Protection from excitotoxic death Microglia S1P1, S1P2, S1P3 and S1P5 Reduced microglial activation Enhanced microgliosis Blood-brain Barrier Reduced leakiness Astrocyte S1P1, S1P2, S1P3 and S1P5 Inhibition of p

  32. Slide 32: LP659 Favorable Efficacy and Safety Results in Preclinical MOG-EAE Model

    LP659 Favorable Efficacy and Safety Results Observed in Preclinical MOG-EAE Model MOG-EAE is a widely accepted model of demyelinating disease (ex. MS) Pretreatment of LP659 reduced incidence and disease severity of MOG-EAE in murine model LP659 rapidly reduced circulating lymphocytes, which returned

  33. Slide 33: LP659 Summary

    LP659 Summary Designed to provide centrally acting S1P receptor modulation, with no impact on S1P2 or 3 High brain to plasma ratio suggests LP659 has the potential to address a wide range of neurodegenerative diseases Oral bioavailability with rapid onset and offset of action LP659: Designed to be a

  34. Slide 34: Financial Summary & Key Milestones

    Financial Summary & Key Milestones Financial Summary Cash, Cash Equivalents & Investments $112.6 million As of September 30, 2021 Shares Outstanding* 17.2 million As of November 2, 2021 YTD Sep-21 Operating Expenses $19.0 million R&D - $13.4 million G&A - $5.6 million Completed and Expected Key Mile

  35. Slide 35: Longboard Pharmaceuticals

    LONGBOARD PHARMACEUTICALS Nasdaq: LBPH

Longboard Pharmaceuticals — Investor Presentation (December 2021) on 6ix